Fulcrum Therapeutics, Inc. SEC filings

Filings

Every filing, newest first. MAJOR and NOTABLE filings lead the app's feed; ROUTINE ones are kept here.

1. ROUTINES-4/AFulcrum Therapeutics, Inc.FULCOct 8

   Fulcrum Therapeutics merges with Slate Medicines

   • Form S-4/A filed on 2026-10-08
   • Merger with Slate Medicines, Inc.
   • Exchange ratio of 24.8186 shares of Fulcrum per Slate share
2. ROUTINE144Fulcrum Therapeutics, Inc.FULCSep 2

   Greg Tourangeau, planned sale of FULC shares

   Greg Tourangeau, reporting

3. NOTABLES-4Fulcrum Therapeutics, Inc.FULCSep 2

   Merger registration

4. ROUTINE425Fulcrum Therapeutics, Inc.FULCAug 17

   Merger communication

5. ROUTINE425Fulcrum Therapeutics, Inc.FULCAug 17

   Merger communication

6. ROUTINE425Fulcrum Therapeutics, Inc.FULCAug 17

   Merger communication

7. ROUTINE8-KFulcrum Therapeutics, Inc.FULCAug 17

   Current report

8. ROUTINESCHEDULE 13G/AFulcrum Therapeutics, Inc.FULCAug 14

   4 13G filings

   Ownership stake disclosure by RA CAPITAL MANAGEMENT, L.P. (amended)

   Show all 4

   • SCHEDULE 13G/AOwnership stake disclosure (amended)Aug 14
   • SCHEDULE 13GOwnership stake disclosureAug 14
   • SCHEDULE 13G/AOwnership stake disclosure (amended)Aug 14
   • SCHEDULE 13G/AOwnership stake disclosure (amended)Aug 14

   RA CAPITAL MANAGEMENT, L.P., filed by

9. ROUTINE8-KFulcrum Therapeutics, Inc.FULCAug 10

   Current report

10. ROUTINESCHEDULE 13GFulcrum Therapeutics, Inc.FULCAug 3

    Ownership stake disclosure by BANK OF AMERICA CORP /DE/

    BANK OF AMERICA CORP /DE/, filed by

11. NOTABLE10-QFulcrum Therapeutics, Inc.FULCJul 30

    Quarterly report

12. ROUTINESCHEDULE 13G/AFulcrum Therapeutics, Inc.FULCJul 28

    Ownership stake disclosure by BlackRock, Inc. (amended)

    BlackRock, Inc., filed by

13. ROUTINE4Fulcrum Therapeutics, Inc.FULCJul 20

    Kevin Tang, insider filing for FULC

    Kevin Tang, reporting · TANG CAPITAL MANAGEMENT LLC, reporting

14. ROUTINESCHEDULE 13GFulcrum Therapeutics, Inc.FULCJul 17

    Ownership stake disclosure by BlackRock Portfolio Management LLC

    BlackRock Portfolio Management LLC, filed by

15. ROUTINESCHEDULE 13G/AFulcrum Therapeutics, Inc.FULCJul 15

    Ownership stake disclosure by TANG CAPITAL MANAGEMENT LLC (amended)

    TANG CAPITAL MANAGEMENT LLC, filed by

16. ROUTINE4Fulcrum Therapeutics, Inc.FULCJul 15

    2 insider filings

    Kevin Tang, insider filing for FULC

    Show all 2

    • 4Insider filing for FULCJul 15
    • 3New insider at FULCJul 15

    Kevin Tang, reporting · TANG CAPITAL MANAGEMENT LLC, reporting

17. ROUTINE4Fulcrum Therapeutics, Inc.FULCJul 2

    8 insider filings

    Sonja Banks, insider filing for FULC

    Show all 8

    • 4Insider filing for FULCJul 2
    • 4Insider filing for FULCJul 2
    • 4Insider filing for FULCJul 2
    • 4Insider filing for FULCJul 2
    • 4Insider filing for FULCJul 2
    • 4Insider filing for FULCJul 2
    • 4Insider filing for FULCJul 2
    • 4Insider filing for FULCJul 2

    Sonja Banks, reporting

18. ROUTINE4Fulcrum Therapeutics, Inc.FULCJun 30

    Alan Ezekowitz, insider filing for FULC

    Alan Ezekowitz, reporting

19. ROUTINE144Fulcrum Therapeutics, Inc.FULCJun 26

    Alan Ezekowitz, planned sale of FULC shares

    Alan Ezekowitz, reporting

20. ROUTINESCHEDULE 13GFulcrum Therapeutics, Inc.FULCJun 25

    2 13G filings

    Ownership stake disclosure by EcoR1 Capital, LLC

    Show all 2

    • SCHEDULE 13GOwnership stake disclosureJun 25
    • SCHEDULE 13GOwnership stake disclosureJun 25

    EcoR1 Capital, LLC, filed by

21. ROUTINE8-KFulcrum Therapeutics, Inc.FULCJun 25

    Current report

22. ROUTINE8-KFulcrum Therapeutics, Inc.FULCJun 11

    Current report

23. ROUTINESCHEDULE 13GFulcrum Therapeutics, Inc.FULCJun 10

    Ownership stake disclosure by TANG CAPITAL MANAGEMENT LLC

    TANG CAPITAL MANAGEMENT LLC, filed by

24. ROUTINE8-KFulcrum Therapeutics, Inc.FULCJun 4

    Current report

25. ROUTINE8-KFulcrum Therapeutics, Inc.FULCJun 1

    Current report

26. ROUTINESCHEDULE 13G/AFulcrum Therapeutics, Inc.FULCMay 15

    2 13G filings

    Ownership stake disclosure by Nantahala Capital Management, LLC (amended)

    Show all 2

    • SCHEDULE 13G/AOwnership stake disclosure (amended)May 15
    • SCHEDULE 13G/AOwnership stake disclosure (amended)May 15

    Nantahala Capital Management, LLC, filed by

27. ROUTINE4Fulcrum Therapeutics, Inc.FULCMay 1

    2 insider filings

    Joshua Lehrer-Graiwer, insider filing for FULC

    Show all 2

    • 4Insider filing for FULCMay 1
    • 3New insider at FULCMay 1

    Joshua Lehrer-Graiwer, reporting

28. ROUTINEDEFA14AFulcrum Therapeutics, Inc.FULCApr 30

    Additional proxy materials

29. ROUTINEARSFulcrum Therapeutics, Inc.FULCApr 30

    Annual report to shareholders

30. ROUTINEDEF 14AFulcrum Therapeutics, Inc.FULCApr 30

    Proxy statement

31. NOTABLE10-QFulcrum Therapeutics, Inc.FULCApr 27

    Quarterly report

32. ROUTINE8-KFulcrum Therapeutics, Inc.FULCApr 27

    Current report

33. ROUTINESCHEDULE 13G/AFulcrum Therapeutics, Inc.FULCMar 26

    Ownership stake disclosure by VANGUARD GROUP INC (amended)

    VANGUARD GROUP INC, filed by

34. ROUTINES-8Fulcrum Therapeutics, Inc.FULCFeb 24

    Employee stock plan registration

35. NOTABLE10-KFulcrum Therapeutics, Inc.FULCFeb 24

    Annual report

36. ROUTINE8-KFulcrum Therapeutics, Inc.FULCFeb 24

    Current report

Older filings on EDGAR